Hrishikesh K. Srinagesh

Author

Stanford University ORCID

Also Known As

Hrishikesh K Srinagesh, Hrishikesh K. Srinagesh, Hrishikesh Krishna Srinagesh, Hrishikesh Srinagesh

Publications

601

Citations

H-Index

Concepts

All Affiliations

Stanford University Mayo Clinic in Arizona University of Pennsylvania Massachusetts General Hospital Bambino Gesù Children's Hospital

About

Hrishikesh K. Srinagesh is an author at Stanford University specializing in immunotherapy, immunology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	262
2	Immunology	3	3	262
3	Blood Transplantation	1	1	29
4	Epidemiology	1	1	29
5	Marrow Transplantation	1	1	29

Hrishikesh K. Srinagesh

Publications

495

Citations

H-Index

Page 1

	Year	Citations
Angiotensin II sustains brain inflammation in mice via TGF-β Tobias V. Lanz, Zhaoqing Ding, Peggy P. Ho, Journal of Clinical Investigation Ang Ii TreatmentImmunologyRenal InflammationAng IiImmunotherapy	2010	198
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease Hrishikesh K. Srinagesh, Umut Özbek, Urvi Kapoor, Blood Advances	2019	105
Identification of Naturally Occurring Fatty Acids of the Myelin Sheath That Resolve Neuroinflammation Peggy P. Ho, Jennifer L. Kanter, Amanda Johnson, Science Translational Medicine	2012	63
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study Matthew J. Frank, John H. Baird, Anne Marijn Kramer, The Lancet	2024	45
Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin Stephanie Gergoudis, Zachariah DeFilipp, Umut Özbek, Blood Advances Solid Organ TransplantationImmunodeficienciesImmunologyTransplantation MedicinePathology	2020	35
Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant Mina Aziz, Jay Shah, Urvi Kapoor, Leukemia Graft-versus-host DiseaseTransplantationMarrow TransplantationDisease RiskGvhd Biomarkers	2020	29
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia Hrishikesh K. Srinagesh, Clayton Jackson, Parveen Shiraz, Blood	2024	20

Page 1